AngioGenex (AGGX) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 14, 2019
FIXED ASSETS [Abstract]
Entity Registrant Name	ANGIOGENEX, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		30,386,667
Amendment Flag	false
Entity Central Index Key	0001085596
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash	$ 96,912	$ 19,583
Prepaid expenses and taxes receivable	15,200	33,236
TOTAL CURRENT ASSETS	112,112	52,819
TOTAL ASSETS	112,112	52,819
CURRENT LIABILITIES
Accrued expenses	428,677	427,974
Accrued expenses - related parties	537,600	417,029
Notes payable	1,000	1,000
Notes payable - related parties	123,665	127,750
Accrued interest	45,097	45,067
Accrued interest - related parties	78,736	77,294
TOTAL CURRENT LIABILITIES	1,214,775	1,096,114
LONG-TERM LIABILITIES
Notes payable, related parties	27,450	27,450
TOTAL LONG-TERM LIABILITIES	27,450	27,450
TOTAL LIABILITIES	1,242,225	1,123,564
STOCKHOLDERS' DEFICIT
Preferred stock, 5,000,000 shares authorized, $0.001 par value, no shares issued and outstanding	0	0
Common stock, 150,000,000 shares authorized, $0.001 par value; 30,386,667 and 29,386,667 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	30,387	29,387
Shares issuable, 1,000,000 shares of common stock, respectively	500	0
Additional paid-in capital	6,577,379	5,911,585
Accumulated deficit	(7,738,379)	(7,011,717)
TOTAL STOCKHOLDERS' DEFICIT	(1,130,113)	(1,070,745)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 112,112	$ 52,819

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in Shares)	5,000,000	5,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0
Common Stock
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in Shares)	150,000,000	150,000,000
Common stock, shares issued (in Shares)	30,386,667	29,386,667
Common stock, shares outstanding (in Shares)	30,386,667	29,386,667
Shares Issuable	500,000	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
EXPENSES
Research and development	$ 76,093	$ 22,638	$ 170,511	$ 12,266
General and administrative	69,068	64,045	551,584	252,481
TOTAL OPERATING EXPENSES	145,161	86,683	722,095	264,747
LOSS FROM OPERATIONS	(145,161)	(86,683)	(722,095)	(264,747)
OTHER INCOME (EXPENSES)
Other income (expense)	(76)	331	21	177
Interest Income	0	256	7	515
Interest expense, net	(2,146)	(2,113)	(4,595)	(5,095)
TOTAL OTHER INCOME (EXPENSE)	(2,222)	(1,526)	(4,567)	(4,403)
LOSS BEFORE INCOME TAXES	(147,383)	(88,209)	(726,662)	(269,150)
INCOME TAXES (BENEFIT)	0	0	0	0
NET LOSS	$ (147,383)	$ (88,209)	$ (726,662)	$ (269,150)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED	$ 0	$ 0	$ (.02)	$ (.01)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK SHARES OUTSTANDING - BASIC AND DILUTED	30,392,162	29,386,667	30,312,081	29,386,667

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Shares Issuable	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2017	$ 29,387	$ 5,892,359		$ (6,576,269)	$ (654,523)
Beginning Balance, Shares at Dec. 31, 2017	29,386,667
Stock-based compensation		(10,530)		0	(10,530)
Net Loss				(180,941)	(180,941)
Ending Balance, Amount at Mar. 31, 2018	$ 29,387	5,881,829		(6,757,210)	(845,994)
Ending Balance, Shares at Mar. 31, 2018	29,386,667
Beginning Balance, Amount at Dec. 31, 2017	$ 29,387	5,892,359		(6,576,269)	(654,523)
Beginning Balance, Shares at Dec. 31, 2017	29,386,667
Net Loss					(269,150)
Ending Balance, Amount at Jun. 30, 2018	$ 29,387	5,900,391		(6,845,419)	(915,641)
Ending Balance, Shares at Jun. 30, 2018	29,386,667
Beginning Balance, Amount at Mar. 31, 2018	$ 29,387	5,881,829		(6,757,210)	(845,994)
Beginning Balance, Shares at Mar. 31, 2018	29,386,667
Stock-based compensation		18,562			18,562
Net Loss				(88,209)	(88,209)
Ending Balance, Amount at Jun. 30, 2018	$ 29,387	5,900,391		(6,845,419)	(915,641)
Ending Balance, Shares at Jun. 30, 2018	29,386,667
Beginning Balance, Amount at Dec. 31, 2018	$ 29,387	5,911,585	$ 0	(7,011,717)	(1,070,745)
Beginning Balance, Shares at Dec. 31, 2018	29,386,667
Sale of common stock, shares	1,000,000
Sale of common stock, value	$ 1,000	199,000	0	0	200,000
Stock-based compensation		392,294	0	0	392,294
Net Loss				(579,279)	(579,279)
Ending Balance, Amount at Mar. 31, 2019	$ 30,387	6,502,879		(7,590,996)	(1,057,730)
Ending Balance, Shares at Mar. 31, 2019	30,386,667
Beginning Balance, Amount at Dec. 31, 2018	$ 29,387	5,911,585	0	(7,011,717)	(1,070,745)
Beginning Balance, Shares at Dec. 31, 2018	29,386,667
Net Loss					(726,662)
Ending Balance, Amount at Jun. 30, 2019	$ 30,387	6,577,379	$ 500	(7,738,379)	(1,130,113)
Ending Balance, Shares at Jun. 30, 2019	30,386,667
Beginning Balance, Amount at Mar. 31, 2019	$ 30,387	$ 6,502,879		$ (7,590,996)	$ (1,057,730)
Beginning Balance, Shares at Mar. 31, 2019	30,386,667
Sale of common stock, shares		74,500	500	0	75,000
Net Loss				$ (147,383)	$ (147,383)
Ending Balance, Amount at Jun. 30, 2019	$ 30,387	$ 6,577,379	$ 500	$ (7,738,379)	$ (1,130,113)
Ending Balance, Shares at Jun. 30, 2019	30,386,667

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (726,662)	$ (269,150)
Adjustments to reconcile net loss to net cash used in operations:
Stock-based compensation - common stock options	392,294	8,032
Changes in operating assets and liabilities:
Prepaid expenses	18,036	17,639
Accounts payable and accrued expenses	16,718	52,907
Accrued expenses - related party	120,571	(38,757)
Accrued interest	30	(6,044)
Accrued interest - related parties	1,442	3,079
Net cash used by operating activities	(177,571)	(232,294)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of financed insurance premiums	(16,015)	0
Repayment of notes payable	(4,085)	(10,000)
Proceeds from the sale of common stock	275,000	0
Net cash provided by financing activities	254,900	(10,000)
Net (decrease) increase in cash	77,329	(242,294)
Cash, beginning of period	19,583	493,676
Cash, end of period	96,912	251,382
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest and income taxes: Interest paid	3,124	8,086
Cash paid for interest and income taxes: Income taxes	$ 0	$ 0

NOTE 1 - ORGANIZATION AND DESCR

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS The condensed consolidated financial statements include AngioGenex, Inc. (“AngioGenex” or the “Company”) and its wholly owned subsidiary AngioGenex Therapeutics, Inc. AngioGenex was incorporated in the State of New York on March 31, 1999. AngioGenex is a bio-pharmaceutical company dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer, and macular degeneration.

NOTE 2 - LIQUIDITY AND BASIS OF

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2019
Note 2 - Liquidity And Basis Of Presentation
NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION	NOTE 2 – LIQUIDITY AND BASIS OF PRESENTATION The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred substantial net losses since inception. The future of the Company is dependent upon obtaining additional financing and generating revenue to fund research and development activities and to support operations. However, there is no assurance that the Company will be able to obtain additional financing. Furthermore, there is no assurance that the United States Food and Drug Administration (the “FDA”) will grant future approval of the Company’s prospective products or that profitable operations can be attained as a result thereof. Our financial statements do not include any recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern. The Company anticipates that its principal source of funds for the next year will be the issuance of additional equity or debt instruments for cash. Management plans to seek additional capital from new equity securities issuances that will provide funds needed to increase liquidity, fund internal growth and fully implement its business plan. Based on the Company's current cash usage expectations, management believes it will not have sufficient liquidity to fund its operations through September 2019. Further, management cannot provide any assurance that it is probable that the Company will be successful in accomplishing any of its plans to raise debt or equity financing. Collectively, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.

NOTE 3 - BASIS OF REPORTING AND

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES The accompanying condensed consolidated financial statements reflect the accounts of the Company and its wholly-owned subsidiary and have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany balances and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, these interim unaudited condensed consolidated financial statements contain all of the adjustments of a normal and recurring nature which are considered necessary for a fair presentation of the financial position of the Company and the results of its operations and cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2019, are not necessarily indicative of the operating results for the entire year. The accompanying Condensed Consolidated Balance Sheet at December 31, 2018, was derived from the audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. These financial statements should be read in conjunction with the annual financial statements and related disclosures included in the audited financial statements for the year ended December 31, 2018. The accompanying interim unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described below and elsewhere in these notes. As of June 30, 2019, the Company’s significant accounting policies and estimates remain unchanged from those detailed in the audited financial statements for the year ended December 31, 2018. Recent Accounting Pronouncements Recently Adopted The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard was effective for us from January 1, 2019. The adoption of this standard had no material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. The Company adopted the pronouncement as of January 1, 2019, noting no material impact on the Company’s financial position or results of operations upon adoption.

NOTE 4 - AGREEMENT WITH MEMORIA

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER	6 Months Ended
	Jun. 30, 2019
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER	NOTE 4 – AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (“MSKCC”) In March 2000, in exchange for $30,000, the Company obtained from MSKCC, a related party, an exclusive worldwide right and license in the field of use, including to make, have made, use, lease, commercialize and sell licensed products and to use licensed processes derived from the invention of our two leading drug candidates. In 2014, the Company issued 810,000 shares of common stock in exchange for previously agreed milestone, royalty and sub-license payments. The aforementioned issuance of shares of common stock released the Company from any future obligations and there are no remaining obligations under the agreement. In July 2017, the Company executed a service agreement with MSKCC, a related party, to provide pre-clinical research services in connection with the development and Investigational New Drug (IND) Application for the Company’s lead compound and its derivatives. The effective date of the agreement is February 2, 2017, and $250,000 of fees and costs have been incurred as of June 30, 2019. The Company paid $150,000 in 2017, $75,000 in 2018 and $25,000 in the first quarter of 2019. In March 2019, the Company amended the agreement with MSKCC to include an additional project and as of June 30, 2019 owes $148,850, which is included in accrued expenses - related parties in the financial statements. The estimated total costs of this project are estimated to be $297,700.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
NOTE 5 - ACCRUED EXPENSES	NOTE 5 – ACCRUED EXPENSES Accrued expenses consist of the following: June, 30 December 31, 2019 2018 Professional fees $ 162,845 $ 161,076 Research and development expenses 200,257 185,229 Licenses 50,000 50,000 Other 15,575 31,669 $ 428,677 $ 427,974

NOTE 6 - RELATED PARTY TRANSACT

NOTE 6 - RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2019
Finite-Lived Intangible Assets, Net [Abstract]
NOTE 6 - RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS The Company owes MSKCC, for research and development expenses, $148,850 and $25,000 as of June 30, 2019 and December 31, 2018, respectively, which is included in accrued expenses – related parties in our financial statements. An officer of the Company allows the Company to use space in his offices for file keeping and other business purposes. The Company pays no rent for this space. This same officer also provides services to the Company in the form of accounting, bookkeeping and tax preparation, for which the Company is billed. As of June 30, 2019 and December 31, 2018, the Company owed the officer’s business $156,596 and $159,868, respectively, which is included in accrued expenses – related parties in our financial statements. At June 30, 2019 and December 31, 2018, the Company owed a former officer $95,000 for unpaid salary pursuant to an agreement. In addition, two former officers are owed $99,159 for unreimbursed business expenses as of June 30, 2019 and December 31, 2018, respectively, which is included in accrued expenses - related parties in our financial statements. Two shareholders provided legal services to the Company, for which the Company is billed. As of June 30, 2019 and December 31, 2018, the Company owed these shareholders $37,995 and $38,002, respectively, which is included in accrued expenses – related parties in the financial statements.

NOTE 7 - FINANCED INSURANCE PRE

NOTE 7 - FINANCED INSURANCE PREMIUMS	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
NOTE 7 - FINANCED INSURANCE PREMIUMS	NOTE 7 – FINANCED INSURANCE PREMIUMS In August 2018, the Company entered into an agreement to finance $29,055 of its insurance premiums. The agreement provides for monthly repayments of principal and interest accrued at 8.54% per annum, commencing on September 10, 2018. At June 30, 2019 the balance was $2,736 and has been included with accrued expenses in the financial statements.

NOTE 8 - NOTES PAYABLE

NOTE 8 - NOTES PAYABLE	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
NOTE 8 - NOTES PAYABLE	NOTE 8 – NOTES PAYABLE At June 30, 2019, the Company’s loans from related parties total $151,115 of principal and accrued interest of $78,736. The interest rate on these notes vary from 0% to 6%. Related parties include directors, officers, stockholders and stock option holders. At June 30, 2019, the Company’s loans from unrelated parties total $1,000 in principal and $816 of accrued interest. The interest rate on these notes is 6%, and the principal and accrued interest is due on demand. On November 19, 2007, the Company obtained an unsecured loan in the amount of $10,000 from an unrelated party. The loan was repaid on April 6, 2018. The Company paid interest payments of $6,171 on March 5, 2018 and $61 on April 6, 2018, totaling $6,232 of interest accrued and paid on this loan. The principal maturity on all of these notes payable (including related parties and non-related parties) is as follows: June 30, 2020 $ 124,665 June 30, 2021 4,700 June 30, 2022 - June 30, 2023 5,250 Thereafter 17,500 $ 152,115

NOTE 9 - CAPITAL STOCK

NOTE 9 - CAPITAL STOCK	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
NOTE 9 - CAPITAL STOCK	NOTE 9 – CAPITAL STOCK Common Stock The Company is authorized to issue 150,000,000 shares of $0.001 par value common stock. In January 2019, the Company sold 1,000,000 shares of common stock to a related party at $0.20 per share for proceeds of $200,000. In June 2019, the Company sold 500,000 shares of common stock to a related party at $0.15 per share for proceeds of $75,000. The shares are issuable as of June 30, 2019.

NOTE 10 - STOCK OPTIONS

NOTE 10 - STOCK OPTIONS	6 Months Ended
	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
NOTE 10 - STOCK OPTIONS	NOTE 10 – STOCK OPTIONS During the six months ended June 30, 2019 the Company granted 3,825,000 options to members of the Board of Directors. The options are fully vested upon grant, exercisable at $0.35 and expire in 5 years. The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions: 2019 Expected life (years) 2.5 years Risk-free interest rate 2.52% Expected dividend yield 0% Expected volatility 63% As of June 30, 2019, 815,000 options are available under the stock option plan approved by the board of directors and the stockholders of the Company on September 27, 2012 (the “2012 Plan”). The following table summarizes information regarding outstanding stock option grants as of June 30, 2019: Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 1.35 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 1.88 0.08 3,370,000 0.08 0.17 1,560,000 0.30 0.17 1,560,000 0.17 0.35 3,825,000 4.55 0.35 3,825,000 0.35 $ 0.01-0.35 15,614,999 2.15 $ 0.14 15,414,999 $ 0.14 No compensation expense has been recognized for the three months ended June 30, 2019 and $18,562 has been recognized for the three months ending June 30, 2018. For the six months ended June 30, 2019 and 2018, the Company recorded compensation expense of $392,294 and $8,032, respectively, for the vested portion of share-based compensation relating to the issuance of stock options. The aggregate intrinsic value of the outstanding and exercisable options at June 30, 2019 was $1,007,983 and $993,563, respectively. At June 30, 2019, all of compensation expense for unvested options has been recognized. During 2016, the Company granted 200,000 stock options to a consultant that will vest upon obtaining certain regulatory approval and submission of an IND application to the FDA. These stock options were accounted for as variable performance based option awards and were adjusted each reporting period to reflect the estimated fair value until such approvals and filings are obtained. The fair value of these options as of June 30, 2018 was $24,001. The change in value of ($8,990) has been included with stock based compensation in research and development for the six months ended June 30, 2018.

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
NOTE 11 - COMMITMENTS AND CONTINGENCIES	NOTE 11 — COMMITMENTS AND CONTINGENCIES In July 2006, Comparative Biosciences Inc. (“CompBio”) , a company that AngioGenex hired to breed and house a colony of its proprietary “Id-Knockout” mice, sued the Company claiming approximately $200,000 in unpaid invoices. AngioGenex’ response included counter-claims for CompBio’s breaches of contract, as well as a number of business torts. On November 6, 2007, the parties agreed to a disposition of the suit under a stipulated judgment and settlement agreement pursuant to which: CompBio must return the laboratory mice and all scientific data from the research, CompBio agreed to forego all intellectual property rights in the mice and in the research that it acknowledged belong to AngioGenex, and AngioGenex agreed to pay CompBio $55,000 in installments over a 5-year period, plus accumulated interest at 5% per annum. The stipulated judgment and settlement agreement was filed with the court in November 2007. The Company has not made the required payments since the fourth quarter of 2008, and is in default of this settlement agreement. Under the terms of the agreement, upon receipt of written notification of default from CompBio the Company has five days to cure. Failure by the Company to cure the default results in an increase in the settlement amount to $75,000 plus retroactive interest of 5% on the balance. The Company has not received any notification of default from CompBio as of report date. In November 2007 and various dates in 2008, the Company has made $17,500 payments to CompBio pursuant to the settlement agreement, and had accrued interest of $44,281. Since those dates, no payments have been made.

NOTE 12 - NET LOSS PER SHARE

NOTE 12 - NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
NOTE 12 - NET LOSS PER SHARE	NOTE 12 — NET LOSS PER SHARE Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and issuable during the periods presented. The computation of diluted loss per share is similar to the computation of basic loss per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. The Company has 15,614,999 and 12,289,999 common stock options outstanding as of June 30, 2019 and 2018, respectively. These options are excluded from the calculation as they are antidilutive.

NOTE 3 - BASIS OF REPORTING A_2

NOTE 3 - BASIS OF REPORTING AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Recent Issued Accounting Pronouncements Recently Adopted	Recent Accounting Pronouncements Recently Adopted The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). ASUs not discussed below were considered by management and either determined to be not applicable or expected to have minimal impact on our consolidated balance sheets or statements of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard was effective for us from January 1, 2019. The adoption of this standard had no material impact on the Company's financial position or results of operations, as the Company has not entered into any lease agreements. In June 2018, FASB issued ASU No. 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of Accounting Standards Codification, or ASC, 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. The Company adopted the pronouncement as of January 1, 2019, noting no material impact on the Company’s financial position or results of operations upon adoption.

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses	June, 30 December 31, 2019 2018 Professional fees $ 162,845 $ 161,076 Research and development expenses 200,257 185,229 Licenses 50,000 50,000 Other 15,575 31,669 $ 428,677 $ 427,974

NOTE 8 - NOTES PAYABLE (Tables)

NOTE 8 - NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Principle maturity on notes payable	June 30, 2020 $ 124,665 June 30, 2021 4,700 June 30, 2022 - June 30, 2023 5,250 Thereafter 17,500 $ 152,115

NOTE 10 - STOCK OPTIONS (Tables

NOTE 10 - STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock options activity	2019 Expected life (years) 2.5 years Risk-free interest rate 2.52% Expected dividend yield 0% Expected volatility 63%
Outstanding stock option grants	Outstanding Exercisable Range of Exercise Prices Granted Stock Options Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted- Average Exercise Price Granted Stock Options Exercisable Weighted- Average Exercise Price $ 0.01-0.05 6,659,999 1.35 $ 0.04 6,659,999 $ 0.04 0.08-0.10 3,570,000 1.88 0.08 3,370,000 0.08 0.17 1,560,000 0.30 0.17 1,560,000 0.17 0.35 3,825,000 4.55 0.35 3,825,000 0.35 $ 0.01-0.35 15,614,999 2.15 $ 0.14 15,414,999 $ 0.14

NOTE 2 - LIQUIDITY AND BASIS _2

NOTE 2 - LIQUIDITY AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Note 2 - Liquidity And Basis Of Presentation
Accumulated deficit	$ (7,738,379)	$ (7,011,717)

NOTE 4 - AGREEMENT WITH MEMOR_2

NOTE 4 - AGREEMENT WITH MEMORIAL SLOAN KETTERING CANCER CENTER (Details) - USD ($)	1 Months Ended	12 Months Ended	29 Months Ended
	Mar. 31, 2000	Dec. 31, 2014	Jun. 30, 2019
Note 4 - Agreement With Memorial Sloan Kettering Cancer Center
MSKCC right and license fee	$ 30,000
MSKCC service agreement fees and costs			$ 250,000
Shares of common stock issued to MSKCC in exchange for previously agreed milestone, royalty and sub-license payments		810,000
Owed to MSKCC as accrued expense related parties			$ 148,850

NOTE 5 - ACCRUED EXPENSES - Acc

NOTE 5 - ACCRUED EXPENSES - Accrued Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Research and development expenses	$ 162,845	$ 185,229
Professional fees	200,257	161,076
Licenses	50,000	50,000
Other	15,575	31,669
Accured Expenses Total	$ 428,677	$ 427,974

NOTE 6 - RELATED PARTY TRANSA_2

NOTE 6 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Owed to MSKCC for research and development expenses	$ 148,850	$ 25,000
Owed to related party business	156,596	159,868
Unpaid salary owed to former officer	95,000	95,000
Owed reimbursed business expenses	99,159	99,159
Legal service fees owed to related party	$ 37,995	$ 38,002

NOTE 7 - FINANCED INSURANCE P_2

NOTE 7 - FINANCED INSURANCE PREMIUMS (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2018	Jun. 30, 2019
Notes to Financial Statements
Amount of insurance premium financed	$ 29,055
Rate of insurance interest accrued per annum	8.54%
Balance due on Insurance premium		$ 2,736

NOTE 8 - NOTES PAYABLE - PRINCI

NOTE 8 - NOTES PAYABLE - PRINCIPLE MATURITY ON NOTES PAYABLE (Details) - USD ($)	60 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Debt Disclosure [Abstract]
Principle maturity		$ 5,250	$ 0	$ 4,700	$ 124,665
Principle maturity total	$ 152,115

NOTE 8 - NOTES PAYABLE (Details

NOTE 8 - NOTES PAYABLE (Details Narrative)	Jun. 30, 2019USD ($)
Debt Disclosure [Abstract]
Loans from related parties- principle	$ 151,115
Loans from related parties- interest	$ 78,829
Max interest rate on related party loans	6.00%
Min interest rate on related party loans	0.00%
Unrelated Party Note total	$ 1,000
Interest accrued on unrelated party advance	$ 816
Interest rate on unrelated party advance	6.00%

NOTE 9 - CAPITAL STOCK (Details

NOTE 9 - CAPITAL STOCK (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Jun. 30, 2019	Jan. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Equity [Abstract]
Common stock, Authorized	150,000,000		150,000,000		150,000,000
Shares issued for cash, duration	500,000	1,000,000
Price per share, duration	$ .15	$ .20
Cash paid for shares, duration	$ 75,000	$ 200,000	$ 275,000	$ 0
Preferred shares outstanding	0		0

NOTE 10 - STOCK OPTIONS (Detail

NOTE 10 - STOCK OPTIONS (Details) - $ / shares	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Stock Options - Number Outstanding	15,614,999	15,614,999	12,289,999
Expected life (years)		2 years 6 months
Risk-free interest rate		2.25%
Expected dividend yield		0.00%
Expected volatility		63.00%
Exercise Price $0.01-0.05
Stock Options - Number Outstanding	6,659,999	6,659,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	1 year 4 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .04	$ .04
Stock Options - Number Exercisable	6,659,999	6,659,999
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.04	$ 0.04
Exercise Price $0.08-0.10
Stock Options - Number Outstanding	3,570,000	3,570,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	1 year 10 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .08	$ .08
Stock Options - Number Exercisable	3,370,000	3,370,000
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.08	$ 0.08
Exercise Price $0.17
Stock Options - Number Outstanding	1,560,000	1,560,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	4 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .17	$ .17
Stock Options - Number Exercisable	1,560,000	1,560,000
Stock Options Exercisable - Weighted Average Exercise Price	$ 0.17	$ 0.17
Exercise Price $0.35
Stock Options - Number Outstanding	3,825,000	3,825,000
Stock Options Outstanding - Average Remaining Contractual Life (in years)	4 years 6 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .35	$ .35
Stock Options - Number Exercisable	3,825,000	3,825,000
Stock Options Exercisable - Weighted Average Exercise Price	$ .35	$ .35
Exercise Price $0.01-0.35
Stock Options - Number Outstanding	15,614,999	15,614,999
Stock Options Outstanding - Average Remaining Contractual Life (in years)	2 years 2 months
Stock Options Outstanding - Weighted Average Exercise Price	$ .14	$ .14
Stock Options - Number Exercisable	15,414,999	15,414,999
Stock Options Exercisable - Weighted Average Exercise Price	$ .14	$ .14

NOTE 10 - STOCK OPTIONS (Deta_2

NOTE 10 - STOCK OPTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock Options Granted			3,825,000
Aggregate intrinsic value of the outstanding and exercisable options	$ 1,007,983		$ 1,007,983
Stock Options Available	815,000		815,000
Compensation expense	$ 0	$ 18,562	$ 392,294	$ 8,032

NOTE 11 - COMMITMENTS AND CON_2

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	131 Months Ended
	Sep. 30, 2018	Dec. 31, 2018	Nov. 06, 2007
Commitments and Contingencies Disclosure [Abstract]
Settlement Agreement amount owed			$ 55,000
Interest rate on settlement agreement, per annum	5.00%
Settlement Agreement payments made	$ 17,500
Settlement Agreement accrued interest		$ 44,281

NOTE 12 - NET LOSS PER SHARE (D

NOTE 12 - NET LOSS PER SHARE (Details Narrative) - shares	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Stock Options - Number Outstanding	15,614,999	12,289,999